- Home
- CCHH vs KPRX Comparison
CCHH vs KPRX Comparison
Compare CCHH & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCHH | KPRX |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | Malaysia | United States |
| Employees | N/A | 13 |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2M | 10.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CCHH | KPRX |
|---|---|---|
| Price | $0.40 | $2.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 69.6K | 62.1K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $43.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $1.76 |
| 52 Week High | $15.39 | $4.18 |
Technical Indicators
Market Signals| Indicator | CCHH | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 33.30 | 55.52 |
| Support Level | $0.36 | $2.25 |
| Resistance Level | $0.68 | $2.94 |
| Average True Range (ATR) | 0.04 | 0.17 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 7.37 | 54.02 |
Price Performance
Historical ComparisonAbout CCHH CCH Holdings Ltd Ordinary Shares
CCH Holdings Ltd operates a hotpot restaurant chain in Malaysia, specializing in chicken hotpot and fish head hotpot, mainly under two brand, namely Chicken Claypot House and Zi Wei Yuan, owned by the wholly owned subsidiaries of the Company. The Company conducts its operations through its wholly owned subsidiaries in Malaysia and is engaged as a restaurant operator, licensor and loyalty owner, and general trader. Currently, the Group has developed a restaurant chain including approximately 15 company-owned restaurant outlets, 13 franchised restaurant outlets in Malaysia, and 4 franchised restaurant outlets outside Malaysia.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.